Fisetin is a flavonol — a subclass of flavonoids found widely in the plant kingdom, most concentrated in strawberries.
Most supplements have one mechanism story. Fisetin has several, and they converge in interesting ways. It’s a senolytic that clears the zombie cells accumulating with age. It’s an anti-inflammatory that suppresses the SASP secretome of senescent cells. It’s a sirtuin activator through indirect pathways. It’s a mitophagy enhancer. It’s a BDNF-upregulator that supports neuroplasticity. And the human clinical trial data, while limited, is better than for most compounds in this space.
Not a miracle pill story. The human evidence has limitations. The dosing and timing questions aren’t fully resolved. But fisetin is one of the better-evidenced additions to a serious longevity supplement protocol, particularly for adults over 50 prioritizing senescent cell clearance and cognitive aging. Understanding its full biochemical profile — rather than just the senolytic headline — reveals why its potential goes beyond what any single mechanism would suggest.
What Is Fisetin? Biochemistry and Dietary Sources
Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a flavonol — a subclass of flavonoids found widely in the plant kingdom. Structurally it’s related to quercetin and kaempferol, sharing the hydroxyflavone backbone but with a distinctive hydroxylation pattern giving it unique biological properties. The specific arrangement of hydroxyl groups at the 3, 3′, 4′, and 7 positions determines its affinity for biological targets — the subtle structural differences between fisetin and quercetin translate into meaningfully different biological activities despite their chemical similarity.
Dietary sources by fisetin concentration (µg/g fresh weight):
Strawberries: 160 µg/g — by far the richest source and the primary fisetin food for most people eating standard diets. A cup of strawberries provides approximately 1-2mg of fisetin depending on variety and ripeness.
Apples: 26.9 µg/g — a medium apple provides roughly 1mg of fisetin, mostly concentrated in the skin
Persimmons: 10.6 µg/g
Lotus root: 5.8 µg/g
Onions: 4.8 µg/g
Grapes: 3.9 µg/g
Kiwi, peaches, cucumber: smaller amounts in the 1-3 µg/g range
The dietary intake of fisetin from even a strawberry-rich diet runs relatively modest — perhaps 2-5mg per day from abundant fruit consumption. The clinical evidence for senolytic effects uses substantially higher doses (hundreds to thousands of milligrams), making supplementation necessary for therapeutic applications. The dietary amounts contribute to the chronic anti-inflammatory and senomorphic effects that accumulate over time, but they’re insufficient for the acute senolytic clearance bursts that require higher concentrations.
Fisetin bioavailability is generally poor (typical of flavonoids), though better than some polyphenols. It undergoes extensive first-pass metabolism in the gut and liver, and gets rapidly glucuronidated and sulfated. Lipid-based delivery systems (oil suspensions, liposomal formulations) improve bioavailability substantially. Taking fisetin with dietary fat increases absorption — a practical consideration for daily dosing.
Senolytic Activity: The Primary Longevity Mechanism
- Significant reduction in senescence markers in multiple tissues (fat, brain, liver, lung) — confirming actual senescent cell clearance, not just symptom improvement
- Improved grip strength and physical endurance relative to untreated old mice
- Reduced markers of systemic inflammation (IL-6, TNF-α, MCP-1) — consistent with SASP reduction from fewer senescent cells
- Improved survival — median lifespan extended approximately 10% with late-life fisetin treatment
- Reduced age-related cognitive decline in behavior tests including recognition memory and spatial memory
The senolytic discovery for fisetin came from the Kirkland lab at Mayo Clinic, published in EBioMedicine in 2018 in a comprehensive screen of natural compounds for senolytic activity. The screen tested multiple flavonoids in human senescent cell cultures and in aged mice, measuring which compounds selectively eliminated senescent cells while sparing normal cells.
Fisetin was the top performer among all natural compounds tested. In comparative testing against quercetin, luteolin, catechin, and other flavonoids, fisetin showed the highest senolytic activity — it more potently and selectively induced apoptosis in senescent human fat progenitor cells, umbilical vein endothelial cells, and bone marrow stromal cells than the other compounds tested.
The mechanism of fisetin’s senolytic activity involves targeting the senescent cell anti-apoptotic pathways (SCAPs) — particularly PI3K/AKT signaling and BCL-2 family pro-survival proteins. Senescent cells upregulate PI3K/AKT and BCL-2/BCL-xL specifically to resist the apoptotic signals that would normally eliminate damaged cells. Fisetin inhibits PI3K, reduces AKT activity, and compromises BCL-2/BCL-xL-mediated survival — selectively in cells that have become dependent on these pathways for survival. Normal cells, with redundant survival pathways, are less affected. This differential sensitivity between senescent and normal cells is the selectivity basis for all practical senolytics.
The dose-selectivity matters: at high concentrations, fisetin is toxic to both senescent and normal cells (as any compound becomes at high enough doses). At the doses used in senolytic protocols (equivalent to approximately 20mg/kg in mice, or 1-2g in humans), the selectivity for senescent cells is maintained based on the differential pathway dependence described above. This therapeutic window defines the senolytic dosing rationale.
The in vivo results in aged mice were dramatic. Old mice (20+ months, equivalent to approximately 70+ human years) treated with fisetin every other month showed:
The combination of tissue-level senescence clearance, physical function improvement, inflammation reduction, cognitive protection, and lifespan extension in a single compound is unusually comprehensive. Most interventions produce effects in one or two domains — the breadth here reflects the scope of SASP-mediated aging that senolytic clearance reverses.
Neuroprotection: The Original Promise
Before fisetin’s senolytic activity was discovered, it was studied primarily as a neuroprotective compound for nearly a decade. This earlier research identified mechanisms that complement and extend the senolytic story, and they remain relevant because the brain is where fisetin’s multiple mechanisms converge most dramatically.
BDNF upregulation:
Brain-derived neurotrophic factor (BDNF) is critical for neuronal survival, synaptic plasticity, and memory formation. Low BDNF associates with depression, anxiety, cognitive decline, and neurodegenerative disease risk. Fisetin increases BDNF expression through transcription factor activation, particularly CREB (cAMP response element binding protein) and AP-1. In multiple rodent models, fisetin treatment increased hippocampal BDNF and improved performance on memory tasks. Distinct from the senolytic activity, and provides a neurological rationale for chronic daily fisetin dosing rather than just pulsed senolytic protocols.
Sirtuin activation:
Fisetin activates SIRT1 through inhibition of SIRT1-suppressing phosphodiesterases, raising cAMP levels and activating the sirtuin pathway. SIRT1 activation in neurons promotes neuronal survival, reduces amyloid production, and activates mitochondrial biogenesis through PGC-1α. The sirtuin activation also contributes to fisetin’s anti-inflammatory effects through SIRT1-mediated NF-κB deacetylation — linking the neuroprotective and anti-inflammatory mechanisms through a common signaling node.
NRF2 activation:
Fisetin activates Nrf2, upregulating antioxidant genes including HO-1 (heme oxygenase-1), NQO1, and glutathione synthesis enzymes. In neurons subjected to oxidative stress — particularly glutamate-induced excitotoxicity — fisetin’s Nrf2-mediated protection is substantial. Especially relevant in contexts of acute neural stress and chronic neuroinflammation.
Anti-tau effects:
Fisetin inhibits tau kinases (particularly CDK5 and GSK-3β) and reduces tau phosphorylation in neuronal models of Alzheimer’s disease. Tau hyperphosphorylation drives neurofibrillary tangle formation — the pathological lesion associated with cognitive decline in Alzheimer’s and other tauopathies. Multiple tau kinase inhibitors have been tested in clinical trials; fisetin represents a dietary compound achieving partial tau kinase inhibition through its multiple-target mechanism.
Amyloid reduction:
Fisetin inhibits amyloid-beta production and aggregation in cell culture and transgenic Alzheimer’s mouse models. The mechanism involves inhibition of beta-secretase (BACE1), which cleaves amyloid precursor protein to generate amyloid-beta fragments. BACE1 inhibition has been a major drug development target for Alzheimer’s — fisetin achieves partial BACE1 inhibition with a profile that’s shown efficacy in animal models without the hepatotoxicity that has complicated pharmaceutical BACE1 inhibitors.
The Alzheimer’s Clinical Data
Results: fisetin supplementation did not significantly improve primary cognitive outcomes versus placebo in the overall group. Subgroup analysis, though, found significant improvements in inflammation biomarkers and modest cognitive function improvements in the subgroup with the highest baseline cognitive impairment. The inflammatory marker improvements are consistent with fisetin’s SASP-suppressive and NF-κB-inhibiting mechanisms.
A modestly disappointing result, but one that should be interpreted carefully. The trial enrolled patients with established Alzheimer’s — late-stage disease where neuronal loss is already extensive. Prevention trials (starting before cognitive decline is apparent) would test a more relevant hypothesis for a compound whose mechanisms include preventing the neuroinflammation and senescence that precede clinical disease. The 6-month duration may be insufficient for neurological effects requiring more prolonged treatment. And the dose (1400 mg/day), while high, sits below what animal-equivalent dosing would suggest for strong senolytic effects.
A 2022 pilot study in cognitively normal adults over 60 found 12 weeks of fisetin supplementation improved several cognitive measures and reduced plasma markers of cellular senescence. This prevention-focused approach is more consistent with fisetin’s likely role — maintaining neurological function with age rather than reversing established disease. The pattern mirrors what’s been observed with most longevity interventions: more effective at prevention than at treating advanced disease.
An ongoing major trial (NCT04323956) is investigating high-dose fisetin for Alzheimer’s prevention in older adults with mild cognitive impairment. Results, expected in the coming years, will substantially clarify fisetin’s role in cognitive aging.
The Anti-Inflammatory Mechanism: Suppressing SASP Without Removing Senescent Cells
Beyond its senolytic activity, fisetin also has senomorphic properties — it suppresses SASP (senescence-associated secretory phenotype) production from senescent cells that survive treatment. This dual activity (senolytic + senomorphic) is unusual and potentially more comprehensive than pure senolytics that only eliminate cells without addressing the SASP of surviving ones.
NF-κB inhibition:
NF-κB is the primary transcription factor driving SASP gene expression. Fisetin inhibits NF-κB activation through multiple mechanisms — inhibits IKKβ (the kinase that activates NF-κB), promotes IκB stability (keeping NF-κB sequestered in the cytoplasm), and directly competes with NF-κB for binding at target gene promoters in some contexts. This NF-κB inhibition also has anti-inflammatory effects in non-senescent cells, contributing to fisetin’s broad anti-inflammatory profile.
mTOR inhibition: mTOR drives SASP translation — the post-transcriptional production of SASP proteins even when SASP gene expression is only moderately elevated. Fisetin inhibits mTOR (through AMPK activation and direct mTOR pathway interactions), reducing SASP protein production even without eliminating the senescent cells themselves. This mTOR-inhibiting activity also contributes to autophagy activation and the metabolic improvements fisetin produces.
Inflammasome inhibition: The NLRP3 inflammasome is activated in senescent cells and contributes to IL-1β and IL-18 production — some of the most inflammatory SASP components. Fisetin inhibits NLRP3 inflammasome assembly and activation, reducing these cytokines specifically. NLRP3 inhibition has become a major target in aging biology because the inflammasome is activated by many aging-associated damage signals and drives the inflammatory cascade connecting cellular damage to tissue dysfunction.
The practical significance of dual senolytic-senomorphic activity: even after a high-dose fisetin treatment reduces senescent cell burden, remaining senescent cells (some resist any single senolytic) keep secreting SASP. Fisetin’s SASP-suppressive activity addresses this residual source of inflammation, potentially providing more complete anti-aging benefit than a pure senolytic would. One reason the hybrid dosing approach — chronic low-dose for ongoing senomorphic benefit plus periodic high-dose for senolytic bursts — makes mechanistic sense.
Exercise, Mitochondria, and the Fisetin Connection
Fisetin’s effects on mitochondrial function and exercise performance represent an underappreciated dimension of its biology. By reducing senescent cell burden in skeletal muscle, fisetin reduces the SASP-mediated inflammatory microenvironment that impairs satellite cell (muscle stem cell) function and muscle repair. Potentially important for maintaining exercise-induced muscle repair and adaptation with age, when satellite cell function declines substantially.
Additionally, fisetin’s AMPK-activating and mTOR-inhibiting effects improve the AMPK/mTOR balance toward the maintenance-oriented state — the same direction as exercise and fasting. This metabolic rebalancing, combined with Nrf2 activation and antioxidant enzyme upregulation, primes the mitochondrial quality control systems that exercise adaptation depends on. Well-functioning mitochondria are the substrate for exercise-induced adaptation; compromised mitochondria limit both the exercise stimulus (reduced ATP for the workout itself) and the adaptive response (impaired mitochondrial biogenesis signaling).
Animal research demonstrates fisetin improves exercise performance in aged mice — consistent with the mechanism of reduced SASP-driven muscle inflammation and improved mitochondrial quality. Whether this translates to meaningful improvements in human athletic performance with age isn’t yet established by RCT data, but the mechanistic case is compelling and consistent with the sarcopenia research showing muscle benefits from senolytic interventions.
One important consideration: fisetin’s AMPK activation and mild mTOR inhibition may blunt mTOR-dependent muscle protein synthesis signaling if taken immediately before or after resistance training. The same timing consideration applying to NAC (discussed elsewhere on this site) applies here — separating fisetin from resistance training sessions by a few hours preserves the anabolic signaling from training while still providing the mitochondrial and anti-senescence benefits at other times.
The Fisetin Dosing Debate: Chronic Low-Dose vs. Pulsed High-Dose
- The argument for pulsed high-dose:
Senolytic activity requires sufficient drug concentrations in tissue to overcome the survival pathways senescent cells depend on. Sub-therapeutic chronic doses may not achieve the required tissue concentration for meaningful senolytic clearance. The animal studies showing senescent cell clearance used intermittent high-dose protocols rather than constant low-dose administration. And senolytics don’t need to be given continuously — once senescent cells are cleared, they don’t immediately return in large numbers, so monthly or quarterly pulsed dosing matches the biology of senescent cell accumulation rates. - The argument for chronic moderate dosing:
Fisetin’s anti-inflammatory, Nrf2-activating, BDNF-upregulating, and sirtuin-activating effects benefit from sustained exposure. Daily lower doses may provide constant senomorphic benefit even when not achieving senolytic concentrations. The cognitive and neuroprotective effects, partly mediated through BDNF and Nrf2, likely require sustained levels rather than periodic peaks — neurotrophic factor expression needs consistent signaling to produce durable changes in synaptic plasticity and neuronal survival. - The practical synthesis: A hybrid protocol makes the most mechanistic sense. Daily moderate-dose supplementation (100-500mg/day taken with fat-containing food) provides the continuous senomorphic and neuroprotective benefits. Monthly or bi-monthly high-dose senolytic bursts (20mg/kg bodyweight for 2 consecutive days — typically 1,000-2,000mg per day for 2 days depending on body weight) attempt the periodic senescent cell clearance requiring higher tissue concentrations. This approach lines up with the clinical thinking of researchers studying senolytics and provides both categories of benefit without requiring the continuous high dosing the Alzheimer’s trial used.
Fisetin and Immune Aging
One less-discussed application of fisetin is its effects on immune aging — the progressive deterioration of immune function that increases infection susceptibility, impairs vaccine responses, and contributes to the chronic inflammation that accelerates multiple age-related diseases.
Senescent immune cells (particularly exhausted T cells and senescent NK cells) accumulate with age and are major contributors to the chronic inflammation of immunosenescence. These cells don’t just fail to function — they actively secrete inflammatory SASP components that damage surrounding tissue and suppress the function of remaining healthy immune cells. Senolytic clearance of these exhausted immune cells in animal models restores T cell repertoire diversity and improves adaptive immune responses.
Fisetin has direct effects on T cell function beyond senolytic clearance. It inhibits T cell exhaustion markers, maintains cytotoxic T cell effector function, and reduces the regulatory T cell-mediated suppression that limits anti-tumor and anti-viral immunity with age. These direct T cell effects complement the senolytic clearance of exhausted cells to provide more comprehensive immune restoration.
In the context of cancer prevention — one of the primary challenges of aging — immune surveillance depends on cytotoxic T cells and NK cells maintaining their ability to detect and eliminate aberrant cells. Age-related decline in this surveillance function is a major reason cancer incidence rises dramatically after 60. Interventions maintaining immune surveillance could have significant implications for cancer prevention, and fisetin’s combination of senolytic activity and direct immune cell function support makes it a candidate for this role.
Human data on fisetin’s immune effects is limited but directionally consistent with the animal findings. Several trials have measured immune markers as secondary outcomes and found improvements in inflammatory cytokines and senescence-associated markers. Dedicated immune endpoint trials are needed to characterize the magnitude and consistency of fisetin’s immune aging effects.
Fisetin vs. Other Senolytics: The Comparison
For adults building a senolytic strategy, the choice between fisetin, quercetin (with or without dasatinib), navitoclax, and other emerging senolytics requires understanding their comparative profiles in terms of potency, selectivity, accessibility, and safety.
- Fisetin vs. quercetin alone: In the Kirkland lab screen, fisetin outperformed quercetin as a senolytic in all cell types tested. At equivalent doses, fisetin produced greater senescent cell clearance. Quercetin has a slightly better SASP-suppressive profile in some studies. The combination of fisetin + quercetin is likely more comprehensive than either alone, as their slightly different targeting profiles may cover different senescent cell populations. At typical supplement doses, both are contributing to the anti-aging effect; fisetin contributes more of the senolytic activity and quercetin more of the antioxidant-focused effects.
- Fisetin vs. D+Q (dasatinib + quercetin): D+Q has more human clinical trial evidence, including the landmark IPF trial and the diabetic kidney disease trial. Dasatinib’s addition to quercetin dramatically increases senolytic potency in adipose-derived senescent cells specifically — a cell type fisetin alone targets less efficiently. For adults who can access dasatinib through a physician (it requires a prescription), the D+Q combination has the strongest human evidence. Fisetin is a reasonable OTC alternative or addition, particularly for its brain-specific and endothelial senolytic activity, which D+Q covers less well. The pragmatic approach for many adults: fisetin + quercetin as the accessible OTC senolytic foundation, with the option to add physician-supervised dasatinib if measurable senescent burden warrants more aggressive clearance.
- Fisetin vs. navitoclax: Navitoclax (ABT-263) is a pharmaceutical BCL-2/BCL-xL inhibitor with powerful senolytic activity. More potent than any natural compound in cell clearance studies. The limitation is thrombocytopenia (platelet depletion) at the doses required for full senolytic effect. Fisetin has essentially no serious adverse effects at therapeutic doses, making it the more accessible choice for most adults. Navitoclax’s role is likely in clinical settings where aggressive senolytic clearance is warranted and can be medically supervised, not in routine supplementation protocols.
The Senescent Cell Clearance Timeline: What to Expect
A practical question that comes up when implementing a fisetin protocol: how quickly does senolytic clearance happen, and what signs indicate it’s working?
The mouse data shows measurable senescent cell clearance within 2-7 days of high-dose fisetin administration. In mice, the reduction in tissue p16 and p21 expression (senescence markers) is detectable within this window following administration of 100mg/kg doses — doses that approximate the therapeutic range used in the animal studies. The clearance appears to continue for several days after the fisetin has been metabolized, as apoptotic processes initiated by fisetin’s BCL-2/PI3K-targeting effects complete their course.
In humans, the timeline is less precisely characterized, but several pilot studies have measured serum senescence markers (p16 expression in blood cells, SASP cytokines) at 1-2 weeks after high-dose fisetin treatment and found significant reductions consistent with clearance having occurred. The clinical improvement in the IPF patients treated with D+Q (the most-studied senolytic combination, which includes quercetin with a similar mechanism) was apparent at 3 weeks — suggesting human biological changes occur in the weeks following treatment.
Subjective indicators consistent with senolytic clearance include: reduced general stiffness (particularly morning joint stiffness not explained by other conditions), improved energy and reduced fatigue, and in some people, brief periods of mild inflammatory symptoms in the 24-48 hours after high-dose treatment (as apoptotic senescent cells release their contents before clearance). The inflammatory blip, if it occurs, is typically mild and transient and is a sign that clearance is occurring.
Objective tracking options: before-and-after measurement of serum CRP, IL-6, and GDF15 (all elevated by SASP) provides the most accessible objective signal. Biological age testing using epigenetic clocks (TruAge, Elysium Index) before and after several months of a protocol gives a broader picture of whether aging biology is shifting in the right direction. These are indirect measures — they don’t prove senolytic clearance specifically — but they’re the most practically accessible indicators available outside of research settings.
Fisetin and Longevity in Women: Sex Differences in Senolytic Effects
Most longevity research is conducted primarily in male animals and, historically, male human study populations. Fisetin is an important area to address this gap, because there are known sex differences in senescent cell accumulation rates and SASP composition that affect the optimal senolytic approach.
Postmenopausal women experience accelerated senescent cell accumulation following estrogen withdrawal. Estrogen has direct anti-senescence effects — it reduces oxidative stress, supports cellular repair mechanisms, and has anti-SASP properties. When estrogen levels drop at menopause, the rate of senescent cell accumulation increases, and there’s evidence this acceleration contributes to the rapid increase in cardiovascular disease risk, bone loss, and cognitive vulnerability characterizing the postmenopausal transition.
Clinical trials of senolytics in postmenopausal women are actively being conducted, with fisetin as one of the primary candidates given its safety profile and documented senolytic activity across multiple tissue types. A trial of fisetin in postmenopausal women aged 65 and older (NCT04722926) is investigating its effects on physical function, bone density, and metabolic markers — endpoints particularly relevant for this population.
For women over 50, the senolytic rationale for fisetin is at least as strong as for men, and may be stronger given the accelerated post-menopausal senescent cell accumulation. The neuroprotective effects through BDNF upregulation are also relevant given the increased Alzheimer’s risk women face relative to men in older age groups.
Fisetin in a Complete Longevity Protocol
How does fisetin fit alongside other longevity interventions in a coherent protocol? The key is understanding what each intervention addresses and ensuring complementary rather than redundant coverage.
Fisetin occupies a unique position because of its dual senolytic-senomorphic mechanism plus neuroprotective properties. No other commonly discussed longevity supplement carries this exact combination. Quercetin is primarily senolytic (and requires dasatinib for optimal effect). Spermidine is autophagy-focused without direct senolytic activity. Urolithin A is specifically mitophagy-focused. GlyNAC addresses antioxidant defense. Rapamycin is mTOR-focused with senomorphic effects but not senolytic. Fisetin bridges the senolytic and neuroprotective categories in a way that makes it non-redundant with any of these.
A rational integration: fisetin at 200-500mg/day daily for chronic BDNF, Nrf2, and SASP-suppressive benefits, with monthly or bi-monthly pulsed doses of 1-2g/day for 2 consecutive days for the senolytic clearance protocol. This fits alongside: GlyNAC (daily, for GSH restoration and mitochondrial defense), spermidine (daily, from food or supplement, for EP300-independent autophagy), urolithin A (daily, 500-1000mg, for PINK1/Parkin mitophagy), and periodic fasting (1-3x weekly 16-18 hour fasts for mTOR-mediated autophagy and metabolic benefits).
The combined cost of this stack is significant — roughly $150-300/month depending on brands and doses chosen. Prioritization matters for those who can’t do everything simultaneously. Fisetin and quercetin for the senolytic protocol, GlyNAC for foundational antioxidant defense, and urolithin A or spermidine as the third priority is a reasonable order. The first two are the most differentiated — nothing else provides senolytic clearance and GSH restoration.
The autophagy activators (UA and spermidine) are somewhat substitutable with rigorous fasting if budget requires prioritization.
Common Questions About Fisetin Biochemistry Dietary
Q: How does fisetin compare to quercetin for senolytic effects?
A: The Kirkland lab screen found fisetin a more potent senolytic than quercetin in the cell types tested — it more effectively eliminated senescent cells at comparable concentrations. Quercetin and dasatinib (the most studied senolytic combination) have been tested in more human clinical trials, though, and have more direct human senolytic evidence. Fisetin and quercetin have different cell-type specificity — fisetin may be more potent in brain and adipose tissue; the D+Q combination covers endothelial cells and other types. For comprehensive senolytic coverage, combining fisetin and quercetin (at appropriate doses) may cover more senescent cell populations than either alone.
Q: Is fisetin safe at the high doses used for senolytic protocols?
A: The clinical trial data suggests good tolerability at 1400 mg/day for 6 months (the Alzheimer’s trial). No significant adverse effects were observed. Fisetin at high doses carries theoretical concerns about inhibiting CYP450 enzymes (affecting drug metabolism in people taking multiple medications) and potentially inhibiting platelet aggregation. At the pulsed protocol doses (1-2g for 2 days/month), these effects are transient and unlikely to be clinically significant in healthy adults not on anticoagulant medications. People on blood thinners, immunosuppressants, or multiple prescription medications should discuss with their physician before starting high-dose fisetin.
Q: Does fisetin affect cancer risk?
A: Multiple mechanisms suggest fisetin would reduce cancer risk: senolytic clearance of pre-malignant senescent cells that could otherwise promote malignant transformation in neighboring cells, SASP suppression reducing the inflammatory cancer-promoting environment, anti-proliferative effects on cancer cells through CDK inhibition, anti-angiogenic properties, and immune surveillance maintenance. Cancer research on fisetin sits primarily in cell culture and animal models showing anti-cancer activity against multiple tumor types. The epidemiological data on flavonoid-rich diets and cancer risk is generally supportive. Not a definitive cancer prevention claim, but the mechanistic case runs multi-dimensional and consistent.
Q: Can I get enough fisetin from eating strawberries?
A: For chronic low-dose senomorphic and neuroprotective effects, daily strawberry consumption contributes meaningfully — a cup of strawberries provides 1-2mg fisetin, and consistent daily intake over years has likely contributed to the associations between fruit consumption and reduced age-related disease. For senolytic effects requiring therapeutic doses (hundreds to thousands of milligrams), dietary intake is completely insufficient. The math is simple: hundreds of pounds of strawberries per day would be needed to approximate a senolytic dose. Supplementation is necessary for the senolytic protocol, while dietary fisetin supports the ongoing anti-inflammatory effects.
Q: When should someone start taking fisetin for longevity purposes?
A: The senolytic rationale suggests starting around age 50, when senescent cell burden has accumulated to levels where clearance becomes clinically relevant and where the immune system’s natural clearance capacity has measurably declined. Younger adults with good immune-mediated senescent cell clearance may benefit less from senolytic protocols. For the neuroprotective and anti-inflammatory benefits (BDNF, Nrf2, NF-κB inhibition), starting in the 40s is reasonable given these mechanisms don’t require senescent cell burden to be therapeutic. Earlier use (30s or younger) has less clear rationale and no established evidence for the senolytic application.
Q: How does fisetin bioavailability affect dosing?
A: Fisetin’s poor oral bioavailability is a real limitation affecting dosing calculations. Approximately 30-50% of fisetin is absorbed, and much of what’s absorbed undergoes rapid metabolic conjugation. Liposomal fisetin formulations improve bioavailability by 2-4x in some studies, meaning a 200mg liposomal dose may be equivalent to 400-800mg of standard fisetin. Taking standard fisetin with olive oil or a fat-containing meal improves absorption significantly. The practical implication: using standard (non-liposomal) fisetin for the chronic low-dose protocol, a dose of 200-500mg/day with fat is reasonable. For the pulsed high-dose senolytic protocol, doses of 1-2g with fat get used to achieve the tissue concentrations needed for senolytic activity.
Q: Does fisetin interact with other supplements in a longevity stack?
A: Generally, the combinations are additive or synergistic rather than antagonistic. Fisetin + quercetin provides complementary senolytic coverage across more cell types than either alone. Fisetin + GlyNAC addresses both senescent cell burden (fisetin’s senolytic action) and the cellular antioxidant environment (GlyNAC’s GSH restoration) — complementary and non-redundant mechanisms. Fisetin + spermidine or urolithin A provides senolytic + autophagy activation — different mechanisms. The one theoretical concern is combining fisetin with other strong CYP450 inhibitors (grapefruit compounds, high-dose berberine), which could affect the metabolism of each. At normal doses this isn’t a major practical concern, but it’s worth mentioning for anyone on prescription medications metabolized by CYP3A4 or CYP2C9.
The overall picture on fisetin is this: it’s one of the more mechanistically versatile compounds in the longevity supplement landscape, with documented senolytic activity, senomorphic effects, neuroprotective mechanisms, and safety data comparing favorably with more established interventions. The human evidence is building — not yet definitive for most applications but directionally consistent and mechanistically coherent. For adults over 50 building a thoughtful longevity protocol, fisetin belongs in the conversation alongside quercetin, GlyNAC, urolithin A, and spermidine as complementary interventions addressing the major hallmarks of aging from multiple angles. The combination of its unique dual senolytic-senomorphic action and its brain-specific neuroprotective mechanisms gives it a profile no other single supplement replicates.
The Practical Framework: Applying Fisetin Biochemistry Dietary Sources In Real Life
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map